Effects of a selective endothelin A-receptor antagonist, BQ-123, in salt-loaded stroke-prone spontaneously hypertensive rats.
1. We examined the effects of a selective endothelin A (ETA)-receptor antagonist, BQ-123, on the development of hypertension and organ damage in stroke-prone spontaneously hypertensive rats (SHRSP) given 1% NaCl for 6 weeks. 2. BQ-123 at doses of 0.7, 2.1 and 7.1 mg/day was continuously administered for 6 weeks to 8 week old salt-loaded SHRSP, who were given water containing 1% NaCl for the following 6 weeks, via a subcutaneous osmotic minipump. 3. Development of high blood pressure was accelerated in salt-loaded SHRSP compared with that in non-salt-loaded SHRSP. After 6 weeks of salt-loading, incidence of cerebral infarction, renal sclerosis and renal fibrosis were greater in salt-loaded than non-salt-loaded SHRSP. 4. BQ-123 attenuated the age-related rise in blood pressure in a dose-dependent manner. The effect coincided with reduction in the incidence of cerebral infarction and prevention of renal sclerosis and fibrosis. Kidney function was improved as observed by an increase in glomerular filtration rate and decreases in urinary protein excretion, blood urea nitrogen and fractional sodium excretion. Furthermore, BQ-123 prevented increases in the heart weight/bodyweight ratio and aortic wall thickness in salt-loaded SHRSP. 5. These results suggest that endogenous endothelin-1 (ET-1) and ETA-receptors may be, at least in part, involved in the pathogenesis of hypertension and organ damage in salt-loaded SHRSP.
Okada
M
M
Department of Pharmacology, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Ibaraki, Japan.
Kobayashi
M
M
Maruyama
H
H
Takahashi
R
R
Ikemoto
F
F
Yano
M
M
Nishikibe
M
M
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001806:Blood Urea Nitrogen; D002561:Cerebrovascular Disorders / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D065128:Endothelin Receptor Antagonists; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D007238:Infarction / Q000209:etiology / Q000517:prevention & control; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control; D007677:Kidney Function Tests; D009994:Osmolar Concentration; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011507:Proteinuria; D051381:Rats; D011918:Rats, Inbred SHR; D012964:Sodium / Q000652:urine; D012982:Sodium, Dietary / Q000008:administration & dosage*
D065128:Endothelin Receptor Antagonists; D010456:Peptides, Cyclic; D012982:Sodium, Dietary; D012964:Sodium; C072247:cyclo(Trp-Asp-Pro-Val-Leu)